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Abstract
The lack of reliable, high-throughput tools for characterizing anti-dengue virus (DENV) antibodies in large numbers of serum
samples has been an obstacle in understanding the impact of neutralizing antibodies on disease progression and vaccine
efficacy. A reporter system using pseudoinfectious DENV reporter virus particles (RVPs) was previously developed by others
to facilitate the genetic manipulation and biological characterization of DENV virions. In the current study, we demonstrate
the diagnostic utility of DENV RVPs for measuring neutralizing antibodies in human serum samples against all four DENV
serotypes, with attention to the suitability of DENV RVPs for large-scale, long-term studies. DENV RVPs used against human
sera yielded serotype-specific responses and reproducible neutralization titers that were in statistical agreement with Plaque
Reduction Neutralization Test (PRNT) results. DENV RVPs were also used to measure neutralization titers against the four
DENV serotypes in a panel of human sera from a clinical study of dengue patients. The high-throughput capability, stability,
rapidity, and reproducibility of assays using DENV RVPs offer advantages for detecting immune responses that can be
applied to large-scale clinical studies of DENV infection and vaccination.
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Introduction
Dengue virus (DENV) is a member of the Flavivirus genus in the
family Flaviviridae and consists of four distinct serotypes (DENV-1,
DENV-2, DENV-3, and DENV-4), which are transmitted by Ae.
aegypti and Ae. albopictus mosquitoes. DENV contains a single-
stranded RNA genome of ,10.7 kb that is translated as a single
polyprotein and then cleaved into three structural (C, prM, and E)
and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
NS5) proteins [1]. DENV is the most significant cause of
arthropod-borne viral disease in humans, resulting in an estimated
50 million cases of dengue fever and over 450,000 cases of life-
threatening dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS) each year [2]. DHF/DSS can be fatal in up to 15% of
affected individuals and is most commonly associated with
sequential infection by different serotypes of the virus [3].
Although primary DENV infection may confer lifelong protection
from re-infection with the same serotype, it only provides short-
term protection from infection with additional serotypes [4],
highlighting the need for a dengue vaccine that can confer
persistent and simultaneous protection against all four serotypes of
the virus. The development of such a vaccine continues to be a
significant challenge, made more difficult by the lack of efficient
and reliable screening methods for detecting and evaluating
functional antibodies in human sera.
For over 40 years, the standard test for measuring DENV
neutralization has been the Plaque Reduction Neutralization Test
(PRNT), which measures the inhibition of viral infectivity
(neutralization) as a reduction of plaque formation on a cell
monolayer [5]. PRNT is not only labor intensive and technically
complex, but requires the use of live virus, can vary based on the
ability of a strain to form plaques, and is not readily adaptable to
high-throughput analysis of large numbers of clinical or
epidemiological samples. The limitations of PRNT have prompt-
ed the development of alternative means of detecting DENV
neutralization using microplate ELISAs and flow cytometry-
based assays [6,7,8]. These methods exceed the throughput of
PRNT and demonstrate comparable sensitivity and specificity to
PRNT when used to assay sera from patients after natural
infection or vaccine administration. However, these detection
methods also require the use of live DENV, do not facilitate
genetic manipulation of infectious virions, and cannot always be
readily adapted for large-scale measurements of neutralization
[7].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27252Pseudo-infectious virions that express reporter genes have been
used widely as tools to study several flaviviruses, including West
Nile Virus (WNV) and tick-borne encephalitis virus
[9,10,11,12,13]. Recently, a plasmid-based DENV RVP produc-
tion system was developed as an easier and safer method for the
genetic manipulation of infectious DENV virions and for
measuring DENV infection and neutralization [14,15]. Infection
of permissive cells using DENV RVPs could be monitored directly
by expression of a reporter gene that could be quantified using
standard optical detection platforms. Initial studies primarily used
the DENV RVP system to characterize temperature-dependent
production of DENV-1 and DENV-2 RVPs using novel replicons,
cell lines, and plasmid-based expression vectors. In the current
study, we demonstrate the diagnostic utility of all four serotypes of
DENV RVPs for measuring neutralizing antibodies, focusing on
the suitability of DENV RVPs for large-scale, long-term clinical
and epidemiological studies. DENV RVPs representing all four
serotypes were tested in neutralization assays using both
monoclonal antibodies and human sera, and data sets obtained
using RVPs resulted in accurate neutralization titers comparable
to PRNT. Neutralization titers using DENV RVPs were
reproducible within experiments, across experimental days,
between RVP production lots, and across two different laborato-
ries. We also used DENV RVPs to accurately detect neutralizing
antibodies in human serum samples from patients with primary or
secondary DENV infections. Finally, we show evidence of the
stability of DENV RVPs at 37uC and after long-term cryopres-
ervation. Our results demonstrate that DENV RVPs provide a
safe, rapid, and reproducible reagent for large-scale screening of
sera for neutralizing antibodies, which can facilitate large-scale
epidemiological studies and may help expedite dengue vaccine
development.
Results
DENV RVPs are infectious and antigenically equivalent to
live dengue virus
DENV RVPs are replication-incompetent virus particles that
contain a sub-genomic DENV replicon encoding GFP, packaged
by serotype-specific viral capsid (C), premembrane/membrane
(prM/M), and envelope (E) proteins (Figure 1A). Upon entry into
permissive cells, DENV RVPs express a GFP reporter gene for
quantitative measurement of infection by flow cytometry (Figure
S1). The production of DENV RVPs using a plasmid-based
complementation approach has been described previously [14].
Using this approach, we developed DENV RVPs against all 4
dengue serotypes that are antigenically equivalent to commonly-
used strains in DENV research and vaccine design: DENV-1
(WestPac), DENV-2 (S16803), DENV-3 (CH53489), and DENV-4
(TVP360). We used DENV RVPs to infect Raji DC-SIGN-R cells,
a cell line commonly used for DENV studies that expresses DC-
SIGN-R (CD209L), a C-type lectin adhesion cofactor shown to
significantly enhance infection by enveloped viruses including
DENV [16,17,18,19]. Quantification of GFP signals were directly
Figure 1. DENV RVPs are infectious and antigenically equivalent to live dengue virus. (A) Dengue Reporter Virus Particles (RVPs) are
composed of the proteins capsid (C), premembrane/membrane (prM/M) and envelope (E) from defined DENV strains, and an RNA reporter genome
made from a DENV genomic replicon. (B) Serial dilutions of DENV RVPs representing each serotype were used to infect Raji DC-SIGN-R cells. Forty-
eight hours after infection, cells were analyzed for GFP expression by flow cytometry. Regression analysis shows a linear relationship (R
2.0.98 for
DENV-1; R
2.0.99 for DENV-2; R
2.0.99 for DENV-3; R
2.0.99 for DENV-4) with the amount (ml) of RVPs used for infection (n=4, error bars represent the
standard deviation). (C) Neutralization assays using DENV RVPs were performed with serially diluted monoclonal antibodies 4G2, 3H5, or the control
monoclonal antibody 15F3 for 1 hour prior to infection of Raji DC-SIGN-R cells. Forty-eight hours after infection, cells were quantified for GFP
expression by flow cytometry. All neutralization results are shown normalized to the maximum (uninhibited) infection achieved, defined as 100%
(n=3, error bars represent the standard deviation). The infectious titers of the lots of RVPs used here, calculated based on the number of infected
cells using an RVP input of 50 ml, are as follows: DENV-1: 773,325 infectious units/ml, DENV-2: 422,970 infectious units/ml, DENV-3: 347,292 infectious
units/ml, and DENV-4: 353,995 infectious units/ml.
doi:10.1371/journal.pone.0027252.g001
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a linear correlation (DENV-1, R
2.0.98; DENV-2, R
2.0.99;
DENV-3, R
2.0.99; DENV-4, R
2.0.99) between the extent of
RVP infection and reporter gene expression (Figure 1B). We also
tested a panel of cell lines commonly used in DENV studies,
including BHK-21 and Vero cells, for DENV RVP infectivity. As
expected, we observed varying degrees of infectivity, with the
highest levels of infection occurring on cells expressing DC-SIGN
and DC-SIGN-R (Figure S2). Because of their higher level of
infection with DENV and their ease of use in flow cytometry
assays, non-adherent Raji-DC-SIGN-R cells were used for
subsequent experiments.
The primary humoral immune response generated against
DENV is targeted to the prM/M and envelope proteins on the
virion surface. In order to function as an alternative to live virus in
neutralization assays, DENV RVPs must demonstrate antigenic
equivalence to live DENV. To test the antigenicity of DENV
RVPs, we assayed for antigen-specific neutralization of DENV-1,
DENV-2, DENV-3 and DENV-4 RVPs using monoclonal
antibodies (MAbs) that are cross-reactive against all four DENV
serotypes (4G2), recognize only DENV-2 (3H5), or fail to
neutralize DENV (15F3) [20,21]. To obtain accurate neutraliza-
tion titers, we used an RVP input of 25–50 ml since that gave both
reproducible levels of infection of Raji DC-SIGN-R cells (10–20%)
and resulted in signals within the linear range of detection. Cell
infection rates outside the linear range (e.g. over 50% infection)
could be achieved using optimized lots of RVPs (data not shown).
Our results demonstrate that RVPs representing each of the four
serotypes were neutralized using 4G2 and that only DENV-2
RVPs were neutralized by 3H5, as predicted (Figure 1C). The
control DENV antibody (15F3) had no effect on infectivity for any
serotype of DENV RVPs. These neutralization data suggest that,
as designed, DENV RVPs appear antigenically authentic and can
be used for the accurate detection of neutralizing antibodies
against all four serotypes.
DENV RVPs are stable and infectious following
incubation at 37uC and prolonged cryopreservation
The potential application of DENV RVPs to large-scale studies
of human sera requires understanding the limitations of their use
in practice. The ability to detect neutralization of DENV can be
limited by the stability of the virus under commonly used
experimental conditions, including incubation periods of up to
several hours with neutralizing antibodies or serum and then with
cells. To monitor the stability of DENV RVP preparations during
typical infection assays, we incubated DENV RVPs of all four
serotypes at 4uC, 25uC, or 37uC for up to 10 hours, followed by
infection of Raji DC-SIGN-R cells (Figure 2A–C). DENV RVPs
displayed high levels of infectivity after a 2 hour incubation at all
temperatures and maintained significant infectivity even after
extended incubation times at 4uC and 25uC. These results suggest
that RVPs can withstand typical incubation temperatures (4uCt o
Figure 2. DENV RVPs are infectious under conditions commonly used in neutralization assays and following long-term
cryopreservation. DENV RVPs representing all 4 serotypes were incubated at 4uC( A), 25uC( B), or at 37uC( C) for up to 10 hours, followed by
infection of Raji DC-SIGN-R cells. Forty-eight hours post-infection, cells were analyzed for GFP expression by flow cytometry. At all temperatures,
DENV RVPs remain highly infectious after a 2-hour incubation (a typical incubation period used in neutralization assays, vertical dashed line). (D)A
single preparation of DENV-2 RVPs was aliquoted and frozen at 280uC from 2 days up to 1 year prior to infection of Raji DC-SIGN-R cells. Forty-eight
hours after infection, cells were analyzed for GFP expression by flow cytometry. DENV RVPs showed little or no substantial loss of infectivity after
long-term cryopreservation (n=2, error bars represent the range).
doi:10.1371/journal.pone.0027252.g002
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neutralization assays.
The ability to prepare and store single lots of DENV RVPs for
repeated experimentation can reduce variability associated with
using different batches of reagents in large-scale studies where
repeated measurements of infectivity over extended periods of
time are required. To assess the stability of cryopreserved DENV
RVPs, we assayed the infectivity of a single lot of DENV RVPs
that was stored at 280uC from 2 days up to 12 months. DENV
RVPs cryopreserved for up to 12 months demonstrated similar
infectivity to DENV RVPs cryopreserved for 2 days (Figure 2D),
suggesting that DENV RVPs can be a reliable reagent even for
prolonged experiments. Taken together, our results demonstrate
that DENV RVPs exhibit desirable stability characteristics for a
reagent that could be used in long-term dengue studies.
DENV RVPs can be used to derive reproducible antibody
neutralization titers
Reproducible measurement of neutralization across RVP
batches, test plates, and experimental days is critical for large-
scale use and long-term studies. While reagent manipulations can
be inherently variable from experiment to experiment, batch-
specific factors should not affect neutralization titers. For example,
excess antigen in the form of free E protein, subviral particles, or
defective interfering virions could potentially bind to neutralizing
antibodies to give an aberrant NT50 neutralization value (i.e.,
more antibody would be required to inhibit a given amount of
infectious DENV RVPs) [13]. To test the reproducibility of
neutralization measurements, we performed replicate neutraliza-
tion assays using the monoclonal antibody 4G2 and three dilutions
of a single lot of DENV-2 RVPs. RVPs were reproducibly
neutralized by 4G2 (Figure 3A) and 50% neutralization titers
were not statistically different, independent of RVP antigen input
when in the linear range of detection (Figure 3B, ANOVA,
p.0.05). Similar results were obtained with DENV1, DENV-3,
and DENV-4 RVPs (Figure S3). These data suggest that DENV
RVP preparations obey the laws of mass action [22], do not
contain interfering excess antigen, and thus can be used to
determine accurate neutralization titers. In addition, we observe
similar NT50 values for independent neutralization experiments
performed on four different days (Figure 3C) and across
independently derived lots of all four serotypes of RVPs
(Figure 3D and Figure S3), highlighting the reproducibility
and reliability of RVPs for neutralization assays.
Human sera neutralize DENV RVPs in a serotype-specific
manner
To be useful as a detection reagent for large-scale clinical
dengue studies, DENV RVPs must be able to identify the presence
of neutralizing antibodies in human serum. To test this, we used
DENV RVPs in neutralization assays with a standardized WHO
reference serum panel derived from naturally infected patients that
has been used by laboratories throughout the world to validate
PRNT [23]. This panel consists of sera reactive against each of the
DENV serotypes, one tetravalent serum reactive against all the
serotypes, and one non-reactive control serum. Similar to our
Figure 3. DENV RVPs can be used to derive reproducible antibody neutralization titers. (A) Serial dilutions of a single lot of DENV-2 RVPs
were pre-incubated with the monoclonal antibody 4G2 at room temperature for 1 hour followed by infection of Raji DC-SIGN-R cells. Forty-eight
hours after infection, cells were analyzed for GFP expression by flow cytometry (n=8 for each dilution, error bars represent the standard deviation).
(B)N T 50 values for each replicate for the indicated RVP input were calculated and plotted (the bar represents the mean NT50, boxes show the mean
and standard deviation for each RVP dilution tested). The mean NT50 values for each volume of RVPs tested for neutralization were not statistically
different (ANOVA, p.0.05). (C) A single lot of DENV-2 RVPs was used for independent neutralization experiments performed on four different days in
duplicate (mean and range shown). Mean NT50 values are not statistically different (ANOVA, p.0.05). (D) Independently derived lots of DENV-2 RVPs
were used for neutralization experiments performed in duplicate (mean and range shown). Mean NT50 values are not statistically different across
different lots (ANOVA, p.0.05).
doi:10.1371/journal.pone.0027252.g003
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were completely neutralized by the tetravalent serum (Figure 4).
Homotypic WHO serum against DENV-2, DENV-3 and DENV-
4 demonstrated serotype specific neutralization. Monotypic serum
used against each heterologous serotype did not display any
significant neutralizing activity (Table 1,N T 50 values), consistent
with the observed antigenic specificity of RVPs. The WHO
DENV-1 serum poorly neutralized DENV-1 RVPs (Figure 4
and Table 1), but this result is consistent with previously reported
PRNT values for this weakly neutralizing serum [23]. In contrast,
human serum from a patient with a primary DENV-1 infection
strongly and specifically neutralized DENV-1 RVPs (Table 2). As
expected, control (naı ¨ve) serum failed to neutralize any DENV
RVPs until non-specific inhibition was observed at the highest
concentration tested. To further demonstrate the reproducibility of
data derived using DENV RVPs, the same WHO serum-based
neutralization assays were independently performed in two
different laboratories (IM and UCB). NT50 values obtained in
both laboratories were not statistically different (Table 1, RVPa
and RVPb) (unpaired t-tests, p.0.05), suggesting that DENV
RVPs can be used to derive serotype-specific and reproducible
neutralization titers using human sera.
To quantitatively compare our results to PRNT, mean NT50
values using RVPs with human WHO sera were compared to data
derived using PRNT with live DENV. PRNT NT50 values were
derived from a worldwide validation study of PRNT reproduc-
ibility (Table 1, PRNT) [23]. We found that DENV RVP NT50
values were not statistically different from PRNT NT50 values for
each of the sera tested (Table 1, ANOVA, p.0.05). Thus,
excluding the WHO DENV-1 serum because of its weak general
reactivity, DENV RVP experiments were accurate in identifying
serotype-specific neutralizing activity against homotypic or
tetravalent sera with no false negative titers (i.e., 14 out of 14
assays that were expected to be neutralizing for a particular
serotype were identified as neutralizing to that serotype, bolded
results in Table 1) and no false positive titers (i.e., 24 of 24 assays
using heterotypic or control sera showed little to no neutralizing
activity, non-bolded results in Table 1). These results confirm the
utility of DENV RVPs for accurately identifying and quantifying
neutralizing and serotype-specific antibodies in human sera.
Application of DENV RVPs to Human Clinical Samples
To demonstrate the utility of DENV RVPs for clinical serum
samples, we tested the ability of RVPs to measure serotype-
specific neutralizing antibodies in individuals naturally infected
with DENV. We obtained a panel of 24 longitudinal serum
samples from six patients (representing five primary infections and
one secondary infection, collected at 3, 6, 12, and 18 months post-
symptom onset) participating in a clinical study on dengue at the
Hospital Infantil Manuel de Jesus Rivera (HIMJR) in Managua,
Nicaragua. The infecting serotype for each patient had been
previously determined by RT-PCR and/or virus isolation using
Figure 4. Neutralization of DENV RVPs using WHO human reference sera. DENV RVPs representing each of the four serotypes were pre-
incubated for 1 hour with a WHO reference panel of human primary sera reactive to each RVP serotype (monovalent, squares: anti-DENV-1 serum in
A; anti-DENV-2 in B; anti-DENV-3 in C; anti-DENV-4 in D) or reactive to all serotypes (tetravalent, triangles in all four panels). Naı ¨ve serum was used as
a negative control. After incubation, DENV RVPs were used to infect Raji DC-SIGN-R cells. Forty-eight hours after infection, cells were quantified for
GFP expression by flow cytometry (n=3, error bars represent the standard deviation).
doi:10.1371/journal.pone.0027252.g004
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neutralization assays, in duplicate, using RVPs representing each
of the four DENV serotypes. Neutralization titers (NT50 values)
calculated for each sample tested demonstrate that RVPs correctly
identified the infecting serotype for each of the 5 primary serum
samples (Table 2 and Figure S5). Comparison of NT50 values
across serotypes show titers 4–10 fold higher against the infecting
serotype than the other three serotypes (Table 2 and Figure S4).
As expected, sera from the secondary DENV infection demon-
strated strong neutralization titers against multiple DENV
serotypes, with the highest titer presumably corresponding to the
initial serotype of infection (‘‘original antigenic sin’’ [24]).
Examination of the samples longitudinally over time suggests that
both high levels of homotypic neutralizing antibodies and low
levels of heterotypic neutralizing antibodies were maintained over
an 18 month period and could be accurately measured using
DENV RVPs (Table 2).
Discussion
The development of a plasmid-based production system for
DENV RVPs [14] enables DENV RVPs to be produced at large-
scale and relatively high titer for widespread applications. Here,
we demonstrate the production of DENV RVPs that are
antigenically equivalent to each of the four DENV serotypes,
facilitating the detection of neutralizing activity in human sera.
DENV RVPs can be used for reliable and rapid quantification of
DENV infection using stability and reproducibility metrics
required for large-scale applications such as dengue epidemiolog-
ical studies and vaccine trials. DENV RVPs are stable under
Table 1. Comparison of neutralization titers for human sera obtained by PRNT or RVPs.
DENV-1 (WestPac) DENV-2 (S16803) DENV-3 (CH53489) DENV-4 (TVP360)
Serum PRNT RVPa RVPb PRNT RVPa RVPb PRNT RVPa RVPb PRNT RVPa RVPb
DENV-1 NT50 24 ,10 18 18 12 10 14 ,10 ,10 11 ,10 ,10
n, STDEV 32, 24 3, – 3, 15 32, 48 3, 6 3, 0.3 31, 18 3, – 3, – 31, 4 3, – 3, –
DENV-2 NT50 ,10 ,10 ,10 57 42 32 13 ,10 ,10 11 ,10 ,10
n, STDEV 31, – 3, – 3, – 32, 63 3, 8 3, 3 31, 19 3, – 3, – 31, 6 3, – 3, –
DENV-3 NT50 21 14 ,10 ,10 26 ,10 187 144 79 11 ,10 18
n, STDEV 32, 44 3, 0.4 3, – 31, – 3, 3 3, – 32, 207 3, 54 3, 28 30, 8 3, – 3, 14
DENV-4 NT50 ,10 ,10 ,10 ,10 20 ,10 10 ,10 ,10 135 164 92
n, STDEV 32, – 3, – 3, – 32, – 3, 4 3, – 31, 5 3, – 3, – 32, 134 3, 44 3, 31
DENV-1234 NT50 577 177 211 297 101 154 357 310 314 129 88 165
n, STDEV 32, 475 3, 44 3, 8 32, 313 3, 34 3, 55 32, 312 3, 24 3, 8 33, 146 3, 18 3, 63
Control NT50 ND ,10 ND ND ,10 ND ND ,10 ,10 ND ,10 ,10
n, STDEV – 3, – – – 3, – – – 3, – 3, – – 3, – 3, –
NT50 neutralization titers for sera were obtained using DENV RVPs or conventional PRNT with live virus and are expressed as reciprocal serum dilutions at which viral
infection was inhibited by 50%. All reference sera were obtained from the National Institute of Biological Standards and Controls (NIBSC). RVPa and RVPb values were
obtained from independent experiments performed in different laboratories (IM and UCB) and were compared to PRNT values obtained in an independent study
conducted by the WHO for validation testing of PRNT for DENV clinical studies [23]. All sera were tested at least three times. Mean NT50 values using PRNT and RVPs
were not statistically different (ANOVA, p.0.05). ‘,10’ (non-neutralizing) indicates a calculated NT50 value of ,10 or the failure of the sera to neutralize by at least 50%.
NT50 values ,10 were calculated as 10.0 for statistical analysis. ND=not determined.
doi:10.1371/journal.pone.0027252.t001
Table 2. Application of DENV RVPs to clinical serum samples.
DENV-1 (WestPac) DENV-2 (S16803) DENV-3 (CH53489) DENV-4 (TVP360)
S e r u m 3m 6m 1 2m 1 8m 3m 6m 1 2m 1 8m 3m 6m 1 2m 1 8m 3m 6m 1 2m 1 8m
DENV-1 (DF) 113 128 449 245 ,10 ,10 ,10 ,10 47 48 44 39 42 45 62 133
DENV-1 (DHF) 361 264 274 208 11 ,10 10 ,10 52 66 61 42 73 79 29 ,10
DENV-2 (DHF) ,10 ,10 25 28 104 152 658 429 21 22 49 42 41 16 59 29
DENV-3 (DF) 15 ,10 46 57 ,10 25 30 26 445 578 705 586 132 54 52 80
DENV-3 (DHF) 28 ,10 ,10 15 39 ,10 ,10 ,10 1005 893 824 512 ,10 57 41 44
DENV-2 (secondary) 225 201 ND 342 179 130 ND 158 162 162 ND 152 ,10 37 ND ,10
Longitudinal serum samples taken at 3, 6, 12 and 18 months post-symptom onset from two primary DENV-1, one primary DENV-2, two primary DENV-3, and one
secondary DENV-2 infection were obtained from naturally infected patients in Nicaragua. The serum representing secondary infection was derived from a patient that
was last infected by DENV-2, as determined by RT-PCR and virus isolation. Each serum was used in neutralization assays against each DENV serotype. ‘,10’ (non-
neutralizing) indicates failure of the serum to neutralize by at least 50%. Each sample was run once, in duplicate. DF, Dengue Fever; DHF, Dengue Hemorrhagic Fever.
ND=not determined.
doi:10.1371/journal.pone.0027252.t002
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to define infecting serotypes and quantify neutralization titers
present in human sera. We demonstrate the utility of DENV RVPs
for neutralization assays using both MAbs and human serum and
show that RVPs perform with a high degree of similarity to the
traditional PRNT method of detection.
PRNT has been the conventional method for detecting DENV
neutralizing antibodies for over 40 years [5]. However, data from
a multi-center validation of PRNT within and between laborato-
ries showed a high degree of variability in neutralizing NT50 values
for the same serum samples [23,25]. The large variation associated
with PRNT is due in part to manual manipulations, subjective
visual assessment of plaques, and variability in infectivity using live
DENV preparations. PRNT also cannot be used with many
vaccine strains or clinical isolates of DENV that plaque poorly or
with cell types that do not support plaque formation [26,27]. To
address some of these limitations, alternative assays for detecting
DENV infection and neutralization have been developed,
including microneutralization and flow cytometry [6,7,8]. These
formats have several advantages over PRNT, including single-cell
detection, non-requirement for plaque formation, and relatively
rapid detection (2–5 days post-infection). However, these assays
still rely on live infectious DENV and cannot always be readily
adapted to large-scale, high-throughput detection of neutralizing
antibodies [7].
Protective immunity against all four DENV serotypes is a
requirement for a safe and effective vaccine because, in a process
known as Antibody Dependent Enhancement (ADE), low affinity
or low concentration antibodies are believed to increase infection
rates by binding virus particles and targeting them to cells
expressing the Fcc receptor (FccR) [28,29,30]. We expect that
DENV RVPs will also be useful for measuring ADE in vitro, and
future studies will focus on establishing an infectivity assay using
DENV RVPs in conjunction with cells that express FccRt o
monitor ADE.
Collectively, our results demonstrate that DENV RVPs provide
a safe, fast, reliable, and quantitative platform for measuring
DENV infectivity and for identifying neutralizing antibodies
against all four DENV serotypes. The ability of DENV RVPs to
accurately detect infecting serotypes in serum samples from
patients with primary DENV infections highlights their utility for
clinical applications. DENV RVPs may thus serve as an attractive
alternative to existing methodologies, with particular application
to large-scale studies such as DENV vaccine trials, epidemiologic
surveillance, and high-throughput drug screening.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Review Boards of
the Nicaraguan Ministry of Health and the University of
California, Berkeley. Parents or legal guardians of all subjects
provided written informed consent, and subjects over 5 years of
age provided assent.
Plasmids, Cells Lines, and Reporter Virus Particles
Plasmids encoding DENV structural genes (CprME) and a
DENV GFP replicon are described elsewhere [14]. The following
cell lines were used in this study: 293TREx (Invitrogen), BHK21
clone 15 (Center for Vector borne Diseases, UC Davis), Vero
(ATCC), Raji-DC-SIGN and Raji-DC-SIGN-R (kindly provided
by Robert Doms). All cell lines were grown at 37uCa t5 %C O 2 in
DMEM complete medium (DMEM with 10% FCS and 1%
penicillin-streptomycin and 2 mM L-glutamine) except for Raji-
DC-SIGN cells, which were grown in RPMI with 10% FCS and
1% penicillin-streptomycin and Raji-DC-SIGN-R cells, which
were grown in RPMI with 20% FCS and 1% penicillin-
streptomycin and 2 mM L-glutamine. DENV RVP production
(DENV-1, Western Pacific 74; DENV-2, S16803; DENV-3,
CH53489; DENV-4, TVP360) was performed in 293TREx cell
lines as described [14] [31]. Supernatants containing RVPs were
harvested, passed through 0.45 mm filters, aliquoted, and stored at
280uC. For all experiments, DENV RVPs were rapidly thawed
from cryopreservation in a 37uC water bath and placed on ice for
use in neutralization assays.
Monoclonal Antibodies and Human Sera
The following monoclonal antibodies (MAbs) were used: pan-
DENV 4G2 (ATCC hybridoma [21]), anti-DENV-2 3H5 (ATCC
hybridoma [21]), and anti-DENV-1 NS1 15F3 (ATCC hybrid-
oma). The following convalescent sera from naturally-infected
individuals were obtained from the UK National Institute for
Biological Standards and Controls (NIBSC): monovalent DENV-1
(NIBSC Code 02/300), DENV-2 (NIBSC Code 02/296), DENV-
3 (NIBSC Code 02/274), DENV-4 (NIBSC 02/298); negative
control pre-bleed human sera (NIBSC Code 02/182), and
tetravalent (DENV-1,2,3,4) human sera (NIBSC Code 02/186).
DENV RVP Infection Assay
Raji-DC-SIGN and Raji-DC-SIGN-R cells were plated at a
density of 40,000 cells per well in 96-well plates. DENV RVPs
were diluted with RPMI complete medium and added to cells,
followed by incubation at 37uCi n5 %C O 2. Forty-eight hours
after infection, cells were fixed with 2% paraformaldehyde and
analyzed by flow cytometry for GFP fluorescence. Typical
infection assays used 25–50 ml RVPs and achieved infection rates
of 10–20% (measuring the number of cells gated as GFP-positive
divided by the total number of cells in the well). All neutralization
results are shown normalized to the maximum (uninhibited)
infection achieved. For BHK21 and Vero infection, cells were
plated at a density of 30,000 cells per well in 96 well plates. DENV
RVPs were diluted with DMEM complete medium and added to
cells, followed by incubation at 37uCi n5 %C O 2. Forty-eight
hours after infection, cells were trypsinized, fixed with 2%
paraformaldehyde, and analyzed by flow cytometry for GFP
fluorescence.
DENV RVP Neutralization Assays
Neutralization assays were performed with MAbs or human
serum samples. All serum samples were heat-inactivated at 56uC
for 30 minutes, clarified by brief centrifugation, and filter sterilized
(0.45 mm). DENV RVPs were pre-incubated in RPMI complete
medium for 1 hour at room temperature with slow agitation with
an equal volume of serially diluted antibodies (360 mg/ml to
0.0182 mg/ml pre-dilution, as measured based on the dilution of
antibody prior to combining with RVPs) or 4-fold serially diluted
sera (starting at 1:5 or 1:10 prior to combining with RVPs).
Following incubation with either MAbs or serum, RVPs were
transferred to a 96-well plate, and Raji DC-SIGN-R cells were
added to each well at a density of 40,000 cells per well followed by
incubation at 37uCi n5 %C O 2 for 48 hours. Cells were
subsequently fixed in 2% paraformaldehyde and analyzed for
the percentage of cells expressing GFP by flow cytometry (Guava
Easycyte or Becton-Dickinson LSRII). The percent infection for
each concentration of MAb or serum was calculated, normalized,
and plotted as percent infection versus log10 of the MAb
concentration or the reciprocal serum dilution. The data were fit
to a sigmoidal dose-response curve using Prism (GraphPad
Dengue Reporter Virus Particles
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achieved a 50% reduction in infection (50% neutralization titer,
NT50). Maximum infection was determined in the absence of
antibodies.
Clinical Serum Samples from Dengue Patients
Longitudinal serum samples were obtained from patients 6
months to 14 years of age who were admitted to the National
Pediatric Reference Hospital, Hospital Infantil Manuel de Jesus
Rivera (HIMJR, Managua, Nicaragua), and, after meeting the
inclusion criteria, were enrolled in a dengue study [32,33]. An
individual was considered to be positive for DENV infection if any
of the following four criteria were met: 1) DENV was isolated, 2)
DENV RNA was demonstrated by RT-PCR, 3) an IgM capture
ELISA was negative in the acute-phase serum sample and positive
in the convalescent phase serum sample, or 4) antibody titers as
measured by an inhibition ELISA demonstrated a $4-fold rise in
paired acute and convalescent sera [34]. A primary DENV
infection was defined by antibody titer of ,1:10 (acute) or
antibody titer of ,1:2560 (convalescent), and a secondary DENV
infection was defined by anti-DENV antibody titer of $1:10
(acute) or $1:2560 (convalescent), as determined by an inhibition
ELISA. Daily serum samples were obtained during the acute
phase, and additional samples were collected at 14 days, 3 months,
6 months, 12 months, and 18 months post-symptom onset.
Supporting Information
Figure S1 Quantification of DENV RVP infection by
flow cytometry. Representative flow cytometry plots from
mock- and DENV RVP-infected Raji-DC-SIGNR cells. Percent
RVP infectivity was calculated by measuring the fraction of GFP
positive cells (upper right quadrant, pink) within the total number
of live cells (blue+pink) gated from forward and side scatter plots.
Infected cells above 50% can routinely be achieved, but infectivity
,20% ensures linearity of infection and adherence to the law of
mass action.
(TIF)
Figure S2 DENV RVP infectivity of multiple cell lines.
DENV-2 RVPs were tested for infectivity with a panel of
commonly used cell lines. Forty-eight hours after infection, cells
were analyzed for GFP expression by flow cytometry (n=2, error
bars represent the range). BHK and Vero cells clearly demon-
strated GFP-positive infected cells, but were less efficiently infected
than cells containing the DC-SIGN or DC-SIGN-R cofactors.
(TIF)
Figure S3 DENV RVPs can be used to derive reproduc-
ible antibody neutralization titers. Three independent lots,
each lot tested twice, of (A) DENV-1 RVPs (25 ml), (B) DENV-3
RVPs (3.1 ml), and (C) DENV-4 RVPs (25 ml) were pre-incubated
with the monoclonal antibody 4G2 at room temperature for
1 hour followed by infection of Raji DC-SIGN-R cells. Forty-eight
hours after infection, cells were analyzed for GFP expression by
flow cytometry. Individual neutralization curves are shown for
each replicate. Neutralization assays were performed using serial
dilutions of three independent lots of (D) DENV-1 RVPs, (E)
DENV-3 RVPs, and (F) DENV-4 RVPs, and mean neutralization
curves are shown (n=4–6 for each dilution, error bars represent
the standard deviation). NT50 values for (G) DENV-1 RVPs (H)
DENV-3 RVPs, and (I) DENV-4 RVPs for the indicated RVP
input were calculated and plotted (bars represents the mean NT50,
boxes show the mean and standard deviation for each RVP input
tested).
(TIF)
Figure S4 RVPs demonstrate serotype specificity using
patient serum samples from primary and secondary
DENV infections. Six or twelve-month serum samples from
naturally infected primary DENV-1 (A), primary DENV-2 (B),
primary DENV-3 (C) or secondary DENV-2 (D) patients were
serially diluted and incubated with RVPs from each of the four
DENV serotypes for 1 hour at room temperature before infection
of Raji DC-SIGN-R cells. Forty-eight hours post-infection, cells
were quantified for GFP expression by flow cytometry. The
dashed line depicts 50% neutralization (NT50) (n=2, error bars
represent the range).
(TIF)
Figure S5 Reproducibility of RVP neutralization assays
using human clinical serum. NT50 neutralization titers for a
human DENV-1 serum were obtained using DENV RVPs and
areexpressed as mean reciprocal serum dilutions at which viral
infection was inhibited by 50%. RVPa and RVPb values were
obtained from independent experiments performed in different
laboratories (IM and UCB), and mean NT50 values against
DENV-1 RVPs or DENV-2 RVPs are not statistically different
(unpaired t test, p.0.5), n=3.
(TIF)
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